环磷酰胺联合人免疫球蛋白治疗老年SLE 的有效性及安全性分析

Efficacy and safety of Cyclophosphamide combined with human immunoglobulin in treatment of elderly patients with SLE

摘要:

目的 探讨环磷酰胺联合人免疫球蛋白治疗老年系统性红斑狼疮（SLE）的有效性及安全性。方法 选取2012 年10 月-2014 年2 月该院收治的74 例SLE 患者。采用随机数字表法，将患者分为研究组和对照组。每组37 例。对照组患者给予环磷酰胺治疗。研究组患者给予环磷酰胺联合人免疫球蛋白治疗。对两组患者临床疗效、治疗前后SLE 疾病活动指数（SLEDAI）、24 h 尿蛋白及不良反应发生情况进行比较。结果 与对照组比较，研究组患者临床治疗显效率和总有效率提高，而无效率降低；治疗后SLEDAI 评分和24 h 尿蛋白含量降低，不良反应高血压和高血脂的发生率下降（P <0.05）。结论 环磷酰胺联合人免疫球蛋白不仅能够提高老年SLE 患者的临床疗效，还能进一步降低不良反应的发生率，进而提高老年患者治疗的安全性。

Abstract:

Objective To probe into the efficacy and safety of Cyclophosphamide combined with human immunoglobulin in treatment of elderly patients with systemic lupus erythematosus (SLE). Methods From October 2012 to February 2014, 74 SLE patients were selected in our hospital. With random number table, the patients were divided into study group and control group. There were 37 cases in each group. The patients in the control group were treated with Cyclophosphamide. The patients in the study group were treated with Cyclophosphamide combined with human immunoglobulin. The clinical effect, the systemic lupus erythematosus disease activity index (SLEDAI) before and after treatment, 24-h urine protein and the incidences of adverse reactions were compared between the two groups. Results Compared with the control group, the significant efficiency and total efficiency of clinical treatment were increased, the inefficiency was significantly decreased in the study group. After treatment SLEDAI score and 24-h urine protein level were decreased, the incidences of adverse reactions including hypertension and high blood cholesterol were decreased significantly; and the differences between the two groups were statistically significant (P < 0.05). Conclusions Cyclophosphamide combined with human immunoglobulin could not only improve the clinical treatment efficacy, but also further reduce the incidences of adverse reactions, and improve the treatment safety for elderly patients with systemic lupus erythematosus.